Recent developments - Criteria influencing the clinical uptake of pharmacogenomic strategies

被引：29

作者：

Shah, J ^{[1
]}

机构：

[1] London Sch Econ & Polit Sci, Dept Social Policy, London WC2A 2AE, England

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2004年 / 328卷 / 7454期

关键词：

D O I：

10.1136/bmj.328.7454.1482

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1482 / 1486

页数：5

共 26 条

[1]

[Anonymous], 2001, REVOLUTION R D GENOM

[2]

[Anonymous], MY VERY OWN MED WHAT

[3] Experts predict bleak post-genomic era for drug R&D [J].

Birmingham, K .

NATURE MEDICINE, 2001, 7 (03) :262-262

[4]

BRANCA M, BIO IT WORLD 2002

[5] A regulatory protocol for pharmacogenomics services [J].

Bristol L.A. .

The Pharmacogenomics Journal, 2002, 2 (2) :83-86

[6] Genetic test evaluation: Information needs of clinicians, policy makers, and the public [J].

Burke, W ;

Atkins, D ;

Gwinn, M ;

Guttmacher, A ;

Haddow, J ;

Lau, J ;

Palomaki, G ;

Press, N ;

Richards, CS ;

Wideroff, L ;

Wiesner, GL .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (04) :311-318

[7] The complexities of predictive genetic testing [J].

Evans, JP ;

Skrzynia, C ;

Burke, W .

BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7293) :1052-1056

[8] Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations [J].

Hughes, AR ;

Mosteller, M ;

Bansal, AT ;

Davies, K ;

Haneline, SA ;

Lai, EH ;

Nangle, K ;

Scott, T ;

Spreen, WR ;

Warren, LL ;

Roses, AD .

PHARMACOGENOMICS, 2004, 5 (02) :203-211

[9] Ethical perspectives on pharmacogenomic profiling in the drug development process [J].

Issa, AM .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :300-308

[10] Drug methylation in cancer therapy: lessons from the TPMT polymorphism [J].

Krynetski, E ;

Evans, WE .

ONCOGENE, 2003, 22 (47) :7403-7413

← 1 2 3 →